EU clears €56 billion AbbVie/Allergan deal

The European Commission has approved AbbVie’s $63 billion (€56.6 billion) acquisition of Allergan, subject to the divestment of an Allergan pipeline drug.

Get unlimited access to all Global Competition Review content